GHX Encourages Healthcare Manufacturers to Take a Holistic, Strategic Approach to UDI in the Wake of the U.S. FDA’s Final Ruling

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LOUISVILLE, Colo.--(BUSINESS WIRE)--Today’s long-awaited release of the U.S. Food and Drug Administration’s (FDA) final Unique Device Identification (UDI) rule has far-reaching implications not only for manufacturers, but also for the healthcare community as a whole. While the rule introduces additional, complex requirements for manufacturers, it likewise opens the door to great opportunities. Those manufacturers that take a holistic, strategic approach to UDI can derive operational benefits, while helping their customers capture better data about the products used in patient care.

Help employers find you! Check out all the jobs and post your resume.